News Breaks |
|
|
| March 18, 2013 |
| 04:55 EDT |  | BIIB, BIIB, BIIB, BIIB, BIIB, BIIB, ACOR, ACOR, ACOR, ACOR, ACOR, ACOR, ISIS, ISIS, ISIS, ISIS, ISIS, ISIS, XNPT, XNPT, XNPT, XNPT, XNPT, XNPT | American Academy of Neurology to host annual meeting
2013 Annual Meeting of the AAN to be held in San Diego on March 16-23. |
|
|
News For BIIB;ACOR;ISIS;XNPT From The Last 14 Days Check below for free stories on BIIB;ACOR;ISIS;XNPT the last two weeks. |
|
|
| May 21, 2013 |
| 07:53 EDT |  | XNPT | XenoPort weakness creates buying opportunity, says Wells Fargo
 Subscribe for More Information |
|
| 07:24 EDT | | BIIB | Global Health Care to host a conference
Subscribe for More Information |
|
| 06:23 EDT | | XNPT | XenoPort shares attractive at current levels, says Leerink
Subscribe for More Information |
|
| 05:44 EDT |  | BIIB | Biogen submits application to FDA for approval of Plegridy in RMS
Subscribe for More Information |
|
| May 20, 2013 |
| 16:22 EDT |  | XNPT | On The Fly: Closing Wrap
Subscribe for More Information |
|
| 15:57 EDT | | BIIB | Biogen IMS numbers should not be adjusted down at ISI Group
ISI Group confirmed with Biogen that Tecfidera is not captured by IMS and numbers should not be adjusted downward to reflect free drugs dispensed. |
|
| 13:06 EDT | | XNPT | On The Fly: Midday Wrap
Stocks on Wall Street were modestly higher at midday as the Dow and S&P seek to continue their march higher after closing last week at record levels. ECONOMIC EVENTS: In the U.S., the light domestic economic calendar included the Chicago Fed National Activity index, which slipped to -0.53 for April from its prior reading of -0.23. In Asia, the Hang Seng and Shanghai Composite both climbed after Chinese home prices were reported to have risen in April. COMPANY NEWS: Yahoo (YHOO) confirmed it is buying social media platform Tumblr for $1.1B, as widely reported over the weekend, and promised "not to screw it up" in its press release to announce the deal... Actavis (ACT) agreed to acquire Warner Chilcott (WCRX) in a stock-for-stock transaction valued at approximately $8.5B. The deal, which was approved by the boards of both companies, equates to a value of $20.08 per Warner Chilcott share based on Actavis' closing share price on Friday, the companies said. MAJOR MOVERS: Among the notable gainers were some other companies with M&A news: Acquity Group (AQ) shares more than doubled after Accenture (ACN) agreed to buy the company for $13.00 per American Depositary Share, and Pactera Technology (PACT) gained 31% after receiving a non-binding proposal from a Blackstone (BX) affiliate to be taken private for $7.50 per ADS. Among the noteworthy losers was XenoPort (XNPT), which fell 11% after one of its drugs failed in a Phase III trial for multiple sclerosis spasticity. Also lower were shares of Red Hat (RHT), which slid 4% following a downgrade to Market Perform at BMO Capital. INDICES: Near 1 pm ET, the Dow was up 13.67, or 0.09%, to 15,368.07; the Nasdaq was up 1.13, or 0.03%, to 3,500.10; and the S&P 500 was up 2.18, or 0.13%, to 1,669.65. |
|
| 12:47 EDT |  | XNPT | XenoPort downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information |
|
| 09:26 EDT | | XNPT | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 07:39 EDT | | BIIB | Biogen weekly MS drug scripts up 26.5%, says Citigroup
Citigroup says weekly scripts for Biogen's multiple sclerosis drug Tecfidera were up 26.5% to 1,621. Citi says the launch of Tecfidera is on track to beat Q2 estimates by a wide margin and it keeps a Buy rating on shares of Biogen. |
| |
| 07:34 EDT | | ISIS | UBS to host a conference
Subscribe for More Information |
|
| 07:12 EDT | | ACOR | Acorda Therapeutics says issued additional U.S. patent for AMPYRA
Subscribe for More Information |
|
| 06:36 EDT | | XNPT | XenoPort to host conference call
Conference call to discuss AP Phase 3 clinical trial results and business updates will be held on May 20 at 8:30am. Webcast Link |
|
| 06:34 EDT | | XNPT | XenoPort reports top-line results for Phase 3 trial of Arbaclofen Placarbil
Subscribe for More Information |
|
| May 17, 2013 |
| 08:38 EDT | | XNPT | XenoPort says shipments of Horizant have commenced
XenoPort announced that shipments of Horizant Extended-Release Tablets to its distributor in the United States have commenced. Depending on individual pharmacy ordering patterns, the product is anticipated to be generally available to patients in the first week of June. On May 1, XenoPort re-acquired from GlaxoSmithKline all commercialization rights to Horizant. Prior to the reacquisition of Horizant, GSK experienced manufacturing issues and delays that have resulted in a stockout of the product. |
|
| May 16, 2013 |
| 07:29 EDT | | BIIB | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 14, 2013 |
| 15:09 EDT | | BIIB | Biogen has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. |
|
| May 13, 2013 |
| 11:12 EDT | | BIIB | Biogen MS drug scripts grew 38% week-over-week, says Leerink
Subscribe for More Information |
|
| 07:34 EDT | | BIIB | Biogen says FDA accepts BLA for Eloctate
Subscribe for More Information |
|
| May 10, 2013 |
| 08:00 EDT | | BIIB | Biogen should be bought on weakness before Q2 Tecfidera data, says Stifel
Stifel recommends buying Biogen on any weakness before the company reports Q2 Tecfidera sales data. The firm thinks that any continued strength in Tecfidera prescription data will cause analysts to revise their estimates higher, and it keeps a Buy rating on the shares. |
| |
|
|
|
|
